Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillation

By Amin Alpesh   Stokes Michael   Wu Ning   Gatt Elyse   Makenbaeva Dinara   Wiederkehr Daniel   Boulanger Luke  

Journal of Medical Economics, Vol. 16, Iss. 10, 2013-10 ,pp. : 1193-1202

Informa Healthcare

Access to resources Recommend Favorite

Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US

By Schoof Nils   Schnee Janet   Schneider Gary   Gawlik Melissa   Zint Kristina   Clemens Andreas   Bartels Dorothee B.  

Current Medical Research and Opinion, Vol. 30, Iss. 5, 2014-05 ,pp. : 795-804

Informa Healthcare

Access to resources Recommend Favorite

Beyond Prediction of Stroke Risk in Nonvalvular Atrial Fibrillation

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 63, Iss. 6, 2015-06 ,pp. : 1284-1285

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Phase II, double‐blind, randomized, parallel group, dose‐finding study of the safety and tolerability of darexaban compared with warfarin in patients with non‐valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL‐2)

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 8, 2015-08 ,pp. : 1405-1413

John Wiley & Sons Inc

Access to resources Recommend Favorite

Heparin bridging in warfarin anticoagulation therapy initiation could increase bleeding in non‐valvular atrial fibrillation patients: a multicenter propensity‐matched analysis

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 2, 2015-02 ,pp. : 182-190

John Wiley & Sons Inc

Access to resources Recommend Favorite